Danish biotech company Genmab (CPH: GMAB) closed 4% higher at the end of Wednesday’s trading after announcing an oncology collaboration with US drugmaker AbbVie (NYSE: ABBV).
This broad collaboration agreement is for the joint development and commercialization of three of Genmab’s early-stage investigational bispecific antibody product candidates, and companies have also entered into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
The companies will partner to develop Genmab’s next-generation bispecific antibody programs, epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze